Forum Update: Supporting Community-Led Discussion
The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.
Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:
- Correct any misunderstandings
- Provide guidance when questions remain unanswered after a few days
- Support discussions where official clarification is needed
Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.
Thank you for being part of the conversation.
Mentioning method of administration + brand name in a subject line/preview text where balance cannot be included.
-
What are the guidelines around saying method of admin with the brand name in a subject line/preview text of an email. For example, I understand that if we say "injection" with the brand name in the SL/PT that we need to include balance which we can't but how come for brands where their official brand name is "[brand name] I.V" that we can use that in a SL/PT without needing balance?
-
What are the guidelines around saying method of admin with the brand name in a subject line/preview text of an email. For example, I understand that if we say "injection" with the brand name in the SL/PT that we need to include balance which we can't but how come for brands where their official brand name is "[brand name] I.V" that we can use that in a SL/PT without needing balance?
@mimic909
Generally, when the route of administration is presented as a claim of product merit (e.g. promotional claims such as “convenient oral tablet” or “subcutaneous injection for at-home use”) in an email envelope (i.e. subject line/preview text), it requires fair balance (FB). Please see our "Tips and checklist" document. This principle applies regardless of the dosage form appearing in the proprietary/non-proprietary name (e.g. “PrDrug X (examplumab for IV injection)”.
